Cogent Biosciences, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Cogent Biosciences, Inc. (COGT), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are COGT insiders buying or selling?
In the last 12 months, Cogent Biosciences, Inc. insiders reported 0 open-market purchases ($0) and 7 sales ($383.9M) — net selling of $383.9M. Since April 2018, Trabud has recorded 24 Form 4 filings for COGT: 9 buys ($56.0M) and 15 sells ($385.3M).
Source: SEC EDGAR Form 4
What stands out
- No Cogent Biosciences, Inc. insider made an open-market purchase in the last 12 months; the 7 reported open-market sales totaled $383.9M.
Key Statistics (April 2018 – Aug 31, 2026)
Total Form 4 filings
24
SEC EDGAR
Insider filers
14
Insider buys (9)
$56.0M
Insider sells (15)
$385.3M
Insider sentiment
Net sellingNet insider flow of $329.3M in net selling since April 2018, and $383.9M in net selling over the last 12 months.
Recent COGT insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Arlene Morris | Director | Sale | 45.5K | $37.12 | $1.7M | SEC ↗ |
| Apr 1, 2026 | Fairmount Funds Management LLC | Director | Sale | 7.0M | $34.66 | $242.6M | SEC ↗ |
| Jan 23, 2026 | Fairmount Funds Management LLC | Director | Sale | 3.5M | $36.40 | $127.4M | SEC ↗ |
| Dec 30, 2025 | Evan Kearns | Chief Legal Officer | Sale | 65.0K | $38.70 | $2.5M | SEC ↗ |
| Dec 30, 2025 | John L. Green | Chief Financial Officer | Sale | 77.0K | $38.68 | $3.0M | SEC ↗ |
| Dec 30, 2025 | Jessica Sachs | Chief Medical Officer | Sale | 82.6K | $38.70 | $3.2M | SEC ↗ |
| Dec 30, 2025 | John Edward Robinson | Chief Scientific Officer | Sale | 90.0K | $38.74 | $3.5M | SEC ↗ |
| Jul 14, 2025 | Fairmount Funds Management LLC | Director | Purchase | 2.8M | $9.00 | $25.0M | SEC ↗ |
| Jan 15, 2025 | Cole Pinnow | Chief Commercial Officer | Purchase | 43.8K | $7.60 | $332.4K | SEC ↗ |
| Jun 13, 2023 | Fairmount Funds Management LLC | Other, 10% Owner | Purchase | 800.0K | $12.00 | $9.6M | SEC ↗ |
| Jun 21, 2022 | Fairmount Funds Management LLC | Other, 10% Owner | Purchase | 1.2M | $8.25 | $9.9M | SEC ↗ |
| Apr 29, 2021 | John L. Green | Chief Financial Officer | Sale | 17.8K | $8.86 | $157.8K | SEC ↗ |
| Oct 8, 2020 | Dario Campana | 10% Owner | Sale | 2.0M | $0.39 | $788.4K | SEC ↗ |
| Aug 18, 2020 | Venrock Healthcare Capital Partners III, L.P. | 10% Owner | Purchase | 451.0K | $2.52 | $1.1M | SEC ↗ |
| Mar 26, 2019 | Seth Ettenberg | Chief Scientific Officer | Sale | 11.5K | $4.12 | $47.3K | SEC ↗ |
| Feb 26, 2019 | Seth Ettenberg | Chief Scientific Officer | Sale | 11.5K | $4.25 | $48.9K | SEC ↗ |
| Dec 29, 2018 | Seth Ettenberg | Chief Scientific Officer | Sale | 11.5K | $4.05 | $46.5K | SEC ↗ |
| Nov 27, 2018 | Seth Ettenberg | Chief Scientific Officer | Sale | 11.5K | $7.00 | $80.4K | SEC ↗ |
| Oct 29, 2018 | Seth Ettenberg | Chief Scientific Officer | Sale | 11.5K | $8.46 | $97.2K | SEC ↗ |
| Sep 26, 2018 | Seth Ettenberg | Chief Scientific Officer | Sale | 11.5K | $12.47 | $143.2K | SEC ↗ |
| Apr 5, 2018 | FMR LLC | Other | Purchase | 94.1K | $12.00 | $1.1M | SEC ↗ |
| Apr 3, 2018 | Atlas Venture Fund IX, L.P. | 10% Owner | Purchase | 94.1K | $12.00 | $1.1M | SEC ↗ |
| Apr 3, 2018 | Bruce Booth | Director | Purchase | 94.1K | $12.00 | $1.1M | SEC ↗ |
| Apr 3, 2018 | Liam Ratcliffe | Director | Purchase | 550.0K | $12.00 | $6.6M | SEC ↗ |
Showing the 24 most recent of 24 Form 4 filings for Cogent Biosciences, Inc..
Most active COGT insiders
- Seth Ettenberg6 filings
- Fairmount Funds Management LLC5 filings
- John L. Green2 filings
- Arlene Morris1 filing
- Atlas Venture Fund IX, L.P.1 filing
Ask anything about COGT insider activity
Use Trabud's AI agent to query Cogent Biosciences, Inc.'s Form 4 history in plain English — "Show me COGT CEO purchases this year" or compare it against any other ticker.
Open the AI agentCOGT insider trading FAQ
Are Cogent Biosciences, Inc. insiders buying or selling?
In the last 12 months, Cogent Biosciences, Inc. insiders reported 0 open-market purchases ($0) and 7 sales ($383.9M) — net selling of $383.9M. Since April 2018, Trabud has recorded 24 Form 4 filings for COGT: 9 buys ($56.0M) and 15 sells ($385.3M). Over the full record that is net selling of $329.3M.
How many insiders trade COGT stock?
14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Cogent Biosciences, Inc.. The most recent filing was accepted on Aug 31, 2026.
Where does Trabud get COGT insider trading data?
All COGT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.